{
    "2020-06-24": [
        [
            {
                "time": "",
                "original_text": "医药行业半年度策略报告：紧抓“抗疫”和“自主定价”两大主线",
                "features": {
                    "keywords": [
                        "医药",
                        "抗疫",
                        "自主定价"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "true",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": ""
                }
            },
            {
                "time": "",
                "original_text": "智飞生物等36股获机构买入型评级",
                "features": {
                    "keywords": [
                        "智飞生物",
                        "机构买入",
                        "评级"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "",
                "original_text": "36股今日获机构买入评级9股上涨空间超20%",
                "features": {
                    "keywords": [
                        "机构买入",
                        "上涨空间",
                        "股票"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "",
                "original_text": "医药生物行业2020年中期策略：拥抱疫情后周期投资机会 重点关注意药新基建和医药大消费",
                "features": {
                    "keywords": [
                        "医药生物",
                        "疫情后周期",
                        "新基建",
                        "大消费"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "true",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": ""
                }
            },
            {
                "time": "",
                "original_text": "新冠疫苗又进一步！这个试验Ⅲ期启动，相关股票6天大涨近50%",
                "features": {
                    "keywords": [
                        "新冠疫苗",
                        "试验Ⅲ期",
                        "股票上涨"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "",
                "original_text": "医药行业2020年中期投资策略：坚持高景气赛道+龙头战略",
                "features": {
                    "keywords": [
                        "医药",
                        "高景气赛道",
                        "龙头战略"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": ""
                }
            },
            {
                "time": "",
                "original_text": "智飞生物(300122)公司点评：重组亚单位新冠疫苗获批临床 关注公司管线重磅产品审批进度",
                "features": {
                    "keywords": [
                        "智飞生物",
                        "重组亚单位疫苗",
                        "临床审批"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "",
                "original_text": "全球首个新冠疫苗启动临床lll期！牛市稳了？游资猛增500亿",
                "features": {
                    "keywords": [
                        "新冠疫苗",
                        "临床lll期",
                        "牛市",
                        "游资"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "",
                "original_text": "药企与资本联袂：全球新冠疫苗研发加速度",
                "features": {
                    "keywords": [
                        "药企",
                        "资本",
                        "新冠疫苗",
                        "研发加速度"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            }
        ]
    ]
}